J Appl Biomed 10:1-8, 2012 | DOI: 10.2478/v10136-012-0002-2

Fullerene nanoparticles and their anti-oxidative effects: a comparison to other radioprotective agents

Jiřina Vávrová1,*, Martina Řezáčová2, Jaroslav Pejchal1
1 Department of Radiobiology, University of Defence, Faculty of Military Health Sciences, Hradec Králové, Czech Republic
2 Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University in Prague, Czech Republic

Radiation therapy occupies an important position in the treatment of malignant diseases in spite of the existence of radiation side effects on normal tissues. Thus, substances are being developed which are designed to reduce both the acute and long term radiation effects on healthy tissues. Currently a sulphur-containing compound amifostine (WR2721, ethyol) is used in clinical practice as a radioprotectant. However, it itself has considerable side effects including hypotension (found in 62% of patients), hypocalcaemia, diarrhoea, nausea, and vomiting. Carbon nanospheres, known as fullerenes, and their water soluble derivatives (e.g. C60(OH)24, dendrofullerene DF-1) exert anti-oxidative properties and reduce damage to the DNA in irradiated cells. Water soluble fullerenes are low-toxic substances and thus, are attractive in terms of their use as radioprotectants.

Keywords: ionizing radiation; fullerenes; antioxidant; radioprotection; nanoparticles

Received: August 17, 2011; Revised: October 31, 2011; Published: March 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vávrová J, Řezáčová M, Pejchal J. Fullerene nanoparticles and their anti-oxidative effects: a comparison to other radioprotective agents. J Appl Biomed. 2012;10(1):1-8. doi: 10.2478/v10136-012-0002-2.
Download citation

References

  1. Ali SS, Hardt JI, Quick KL, Sook Kim-Han J, Erlanger BF, Huang TT, Epstein CJ, Dugan LL. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic Biol Med. 37: 1191-1202, 2004. Go to original source... Go to PubMed...
  2. Ali SS, Hardt JI, Dugan LL. SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study. Nanomedicine. 4: 283-294, 2008. Go to original source... Go to PubMed...
  3. Bacq ZM. The amines and particularly cysteamine as protectors against roentgen rays. Acta Radiol. 41: 47-55, 1954. Go to original source... Go to PubMed...
  4. Bakry R, Vallant RM, Najam-ul-Haq M, Rainer M, Szabo Z, Huck CW, Bonn GK. Medicinal applications of fullerenes. Int J Nanomedicine. 2: 639-649, 2007.
  5. Belikova NA, Glumac A, Rafikov R, Jiang J, Greenberger JS, Kagan VE, Bayir H. Radioprotection by short-term oxidative preconditioning: role of manganese superoxide dismutase. FEBS Lett. 583: 3437-3442, 2009. Go to original source... Go to PubMed...
  6. Blumenthal RD, Lew W, Reising A, Soyne D, Osorio L, Ying Z, Goldenberg DM. Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. Int J Cancer. 86: 276-280, 2000. Go to original source...
  7. Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 38: 913-923, 2003. Go to original source... Go to PubMed...
  8. Brown AP, Chung EJ, Urick ME, Shield WP 3rd, Sowers AL, Thetford A, Shankavaram UT, Mitchell JB, Citrin DE. Evaluation of the fullerene compound DF-1 as a radiation protector. Radiat Oncol. 5: 34, 2010. Go to original source... Go to PubMed...
  9. Cai X, Hao J, Zhang X, Yu B, Ren J, Luo C, Li Q, Huang Q, Shi X, Li W, Liu J. The polyhydroxylated fullerene derivative C60(OH)24 protects mice from ionizing-radiation-induced immune and mitochondrial dysfunction. Toxicol Appl Pharmacol. 243: 27-34, 2010. Go to original source... Go to PubMed...
  10. Cheng Y, Li D, Ji B, Shi X, Gao H. Structure-based design of carbon nanotubes as HIV-1 protease inhibitors: atomistic and coarse-grained simulations. J Mol Graph Model. 29: 171-177, 2010. Go to original source... Go to PubMed...
  11. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist. 15: 360-371, 2010. Go to original source... Go to PubMed...
  12. Dostál M. Protective effect of cystamine before radiation (in Czech). PhD. thesis, Purkyně Military Medical Research and Postgraduate Institute, Hradec Králové 1967.
  13. Dugan LL, Gabrielsen JK, Yu SP, Lin TS, Choi DW. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol Dis. 3: 129-135, 1996. Go to original source... Go to PubMed...
  14. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O'Malley KL. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord. 7: 243-246, 2001. Go to original source... Go to PubMed...
  15. Epperly MW, Sikora CA, DeFilippi SJ, Gretton JA, Zhan Q, Kufe DW, Greenberger JS. Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res. 157: 568-577, 2002. Go to original source...
  16. Epperly MW, Dixon T, Wang H, Schlesselman J, Franicola D, Greenberger JS. Modulation of radiation-induced life shortening by systemic intravenous MnSOD-plasmid liposome gene therapy. Radiat Res. 170: 437-443, 2008. Go to original source... Go to PubMed...
  17. France HG, Jr., Jirtle RL, Mansbach CM. Intracolonic WR 2721 protection of the rat colon from acute radiation injury. Gastroenterology. 91: 644-650, 1986. Go to original source... Go to PubMed...
  18. Friedman SH, Ganapathi PS, Rubin Y, Kenyon GL. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation. J Med Chem. 41: 2424-2429, 1998. Go to original source... Go to PubMed...
  19. Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC, Chow H, Tan KW, Wong C, Tan CH, Goh YT. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 34: 51-56, 2004. Go to original source... Go to PubMed...
  20. Injac R, Boskovic M, Perse M, Koprivec-Furlan E, Cerar A, Djordjevic A, Strukelj B. Acute doxorubicin nephrotoxicity in rats with malignant neoplasm can be successfully treated with fullerenol C60(OH)24 via suppression of oxidative stress. Pharmacol Rep. 60: 742-749, 2008. Go to original source... Go to PubMed...
  21. Jensen AW, Wilson SR, Schuster DI. Biological applications of fullerenes. Bioorg Med Chem. 4: 767-779, 1996. Go to original source... Go to PubMed...
  22. Johnston HJ, Hutchison GR, Christensen FM, Aschberger K, Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci. 114: 162-182, 2010. Go to original source... Go to PubMed...
  23. Konopacka M, Widel M, Rzeszowska-Wolny J. Modifying effect of vitamins C, E and beta-carotene against gamma-ray-induced DNA damage in mouse cells. Mutat Res. 417: 85-94, 1998. Go to original source... Go to PubMed...
  24. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 12: 738-747, 2007. Go to original source... Go to PubMed...
  25. Kuna P. Chemical radioprotection (in Czech). Avicenum, Praha 1985.
  26. Kuna P, Volenec K, Vodička I, Dostál M. Radioprotective and hemodynamic effects of WR-2721 and cystamine in rats: time course studies. Neoplasma. 30: 349-357, 1983. Go to PubMed...
  27. Kuna P, Dostál M, Neruda O, Knajfl J, Petýrek P, Podzimek F, Severa J, Svoboda V, Šimša J, Špelda S, Vávrová J, Heřmanská J. Acute toxicity and radioprotective effects of amifostine (WR-2721) or cystamine in single whole body fission neutrons irradiated rats. J Applied Biomed. 2: 43-49, 2004. Go to original source...
  28. Li W, Zhao L, Wei T, Zhao Y, Chen C. The inhibition of death receptor mediated apoptosis through lysosome stabilization following internalization of carboxyfullerene nanoparticles. Biomaterials. 32: 4030-4041, 2011. Go to original source... Go to PubMed...
  29. Liu J, Ohta S, Sonoda A, Yamada M, Yamamoto M, Nitta N, Murata K, Tabata Y. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J Control Release. 117: 104-110, 2007. Go to original source... Go to PubMed...
  30. Malick MA, Roy RM, Sternberg J. Effect of vitamin E on post irradiation death in mice. Experientia. 34: 1216-1217, 1978. Go to original source... Go to PubMed...
  31. Marković Z, Trajković V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials. 29: 3561-3573, 2008. Go to original source... Go to PubMed...
  32. Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR. Photodynamic therapy with fullerenes. Photochem Photobiol Sci. 6: 1139-1149, 2007. Go to original source... Go to PubMed...
  33. Petkau A. Radiation protection by superoxide dismutase. Photochem Photobiol. 28: 765-774, 1978. Go to original source... Go to PubMed...
  34. Piper JR, Stringfellow CR, Jr., Elliott RD, Johnston TP. Terminally substituted S-2-(omega;-Amino-alkylamino) ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents. J Med Chem. 12: 236-243, 1969. Go to original source... Go to PubMed...
  35. Prasad KN, Cole WC, Kumar B, Che Prasad K. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev. 28: 79-91, 2002. Go to original source... Go to PubMed...
  36. Schinazi RF, Sijbesma R, Srdanov G, Hill CL, Wudl F. Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene. Antimicrob Agents Chemother. 37: 1707-1710, 1993. Go to original source... Go to PubMed...
  37. Tabata Y, Murakami Y, Ikada Y. Photodynamic effect of polyethylene glycol-modified fullerene on tumor. Jpn J Cancer Res. 88: 1108-1116, 1997. Go to original source... Go to PubMed...
  38. Trajković S, Dobrić S, Jaćević V, Dragojević-Simić V, Milovanović Z, Dordević A. Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats. Colloids Surf B Biointerfaces. 58: 39-43, 2007. Go to original source... Go to PubMed...
  39. Theriot CA, Casey RC, Moore VC, Mitchell L, Reynolds JO, Burgoyne M, Partha R, Huff JL, Conyers JL, Jeevarajan A, Wu H. Dendro [C60]fullerene DF-1 provides radioprotection to radiosensitive mammalian cells. Radiat Environ Biophys. 49: 437-445, 2010. Go to original source... Go to PubMed...
  40. Vacek A, Rotkovská D, Raková A. The protective effect of hypoxia against repeated irradiation of mice. Int J Radiat Biol Relat Stud Phys Chem Med. 19: 323-328, 1971. Go to original source... Go to PubMed...
  41. Yin JJ, Lao F, Fu PP, Wamer WG, Zhao Y, Wang PC, Qiu Y, Sun B, Xing G, Dong J, Liang XJ, Chen C. The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials. 30: 611-621, 2008. Go to original source... Go to PubMed...
  42. Yudoh K, Karasawa R, Masuko K, Kato T. Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis. Int J Nanomedicine. 4: 217-225, 2009. Go to original source... Go to PubMed...
  43. Yuhas JM. A more general role for WR-2721 in cancer therapy. Br J Cancer. 41: 832-834, 1980. Go to original source... Go to PubMed...
  44. Zherebchenko PG, Suvorov NN. The Relation between the radioprotective and vasoconstrictive action of indolyl alkalylamines (in Russian). Radiobiologiia. 3: 595-602, 1963. Go to PubMed...